Download pdf
Mechanisms of drug resistance in HER2-positive breast cancer cells and methods to overcome
- 1 State/National Key Laboratory of Biotherapy, Sichuan University, Chengdu, Sichuan, 610000, China
* Author to whom correspondence should be addressed.
Abstract
Breast cancer (BC) has become one of the major malignant tumors affecting women's health in recent years, and the expression of human epidermal growth factor HER2 elevates the proliferation and migration of BC tumors. The HER2-targeted drug trastuzumab is initially effective, but resistance can develop after a period of time. There is currently no particularly effective approach to drug resistance in HER2-positive BC. In this paper, we have compiled and summarized several major drug resistance mechanisms of HER2-positive BC cells and proposed several coping strategies, suggesting the possibility of immunotherapy, as well as providing theoretical references for future immunotherapy for the remaining tumors. However, the safety of immunotherapy has not yet been demonstrated, and future studies could focus on ensuring the safety and prognosis of patient treatment.
Keywords
BC, HER2, NK cells, ADCC, ADC, KIR2DL4.
[1]. Cao C 2023 Enhancing ADCC effect to improve the efficacy of trastuzumab in HER2-positive breast cancer Doctoral dissertation People's Liberation Army Air Force Medical University
[2]. Valabrega G Montemurro F & Aglietta M 2007 Trastuzumab: Mechanism of action resistance and future perspectives in HER2-overexpressing breast cancer Ann Oncol 18 6 977-984
[3]. Yang X Xu Y & Shen Z 2023 Mechanisms of resistance to anti-HER2 targeted therapy and new therapeutic strategies Tumor 43 07 580-597
[4]. Wu Z P Xu S G Zhou L H et al 2018 Clinical significance of quantitative HER2 gene amplification as related to its predictive value in breast cancer patients in neoadjuvant setting Onco Targets Ther 11 801-808
[5]. Ocaña A Amir E & Pandiella A 2020 HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates Breast Cancer Res 22 1 15
[6]. Chumsri S Sperinde J Liu H et al 2018 High p95HER2/HER2 ratio associated with poor outcome in trastuzumab-treated HER2-positive metastatic breast cancer NCCTG N0337 and NCCTG 98-32-52 Alliance Clin Cancer Res 24 13 3053-3058
[7]. Menendez J A & Lupu R 2007 Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis Nat Rev Cancer 7 10 763-777
[8]. Hsu J Hodgins J J Marathe M et al 2018 Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade J Clin Invest 128 10 4654-4668
[9]. Hasegawa Y Takanashi S Kanehira Y et al 2001 Transforming growth factor-beta1 level correlates with angiogenesis tumor progression and prognosis in patients with nonsmall cell lung carcinoma Cancer 91 5 964-971
[10]. Zheng G Guo Z Li W et al 2021 Interaction between HLA-G and NK cell receptor KIR2DL4 orchestrates HER2-positive breast cancer resistance to trastuzumab Signal Transduct Target Ther 6 1 236
[11]. von Minckwitz G Procter M de Azambuja E et al 2017 Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer N Engl J Med 377 2 122-131
[12]. Cortés J Kim S B Chung W P et al 2022 Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer N Engl J Med 386 12 1142-1154
[13]. Zhang X Liu S Zhang K et al 2024 Meta-analysis of the efficacy and safety of trastuzumab in the treatment of breast cancer J Pharmacoepidemiol 33 05 539-548
[14]. Ferraro E Drago J Z & Modi S 2021 Implementing antibody-drug conjugates ADCs in HER2-positive breast cancer: State of the art and future directions Breast Cancer Res 23 1 100554
[15]. Chen J Long J B Hurria A et al 2012 Incidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer J Am Coll Cardiol 60 24 2504-2512
[16]. Zheng G X Li W M Guo Z Y et al 2016 Blockade of KIR2DL4 CD158d enhances the killing function of NK cells J Cell Mol Immunol 32 08 1069-1072
[17]. Utikul A & Shi Y 2023 Expression of KIR2DL4 in peripheral blood of patients with acute lymphoblastic leukemia and its effect on NK cell killing function Mod Oncol Med 31 03 450-455
[18]. Guo Y 2023 Expression of HLA-G and KIR2DL4 in colorectal cancer and its clinical significance Doctoral dissertation Lanzhou University
[19]. Yan W 2003 Structure and function of the NK cell receptor KIR2DL4 J Immunol S1 53-56
Cite this article
Chen,D. (2024). Mechanisms of drug resistance in HER2-positive breast cancer cells and methods to overcome. Theoretical and Natural Science,62,45-51.
Data availability
The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.
Disclaimer/Publisher's Note
The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of EWA Publishing and/or the editor(s). EWA Publishing and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
About volume
Volume title: Proceedings of the 4th International Conference on Biological Engineering and Medical Science
© 2024 by the author(s). Licensee EWA Publishing, Oxford, UK. This article is an open access article distributed under the terms and
conditions of the Creative Commons Attribution (CC BY) license. Authors who
publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons
Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this
series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published
version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial
publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and
during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See
Open access policy for details).